A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase II, national, multicenter, open-label, non-comparative study to investigate
the efficacy and safety of bevacizumab and temozolomide in patients with recurrent
glioblastoma multiforme (GBM) after a first treatment failure. Patients will receive
bevacizumab 10 mg/kg intravenously every two weeks until disease progression, consent
withdrawal, or unacceptable toxicity. Anticipated time on study treatment is 12-24 months.